Biomarkers in Pancreatic Neuroendocrine Tumors

  • Maria Serafeim Theochari Oncology Unit, Third Department of Medicine, Sotiria General Hospital. Athens, Greece
  • Konstantinos N Syrigos Oncology Unit, Third Department of Medicine, Sotiria General Hospital. Athens, Greece
  • Muhammad Wasif Saif Department of Medicine and Cancer Center, Tufts Medical Center. Boston, MA, USA
Keywords: Biological Markers, MicroRNAs, Neuroendocrine Tumors, Smad4 Protein


The aim of biomarkers is to identify patients most likely to benefit from a therapeutic strategy. Pancreatic neuroendocrine tumors are rare neoplasms that arise in the endocrine tissues of the pancreas. Pancreatic neuroendocrine tumors represent 3% of primary pancreatic neoplasms and their incidence has risen. The SMAD4 gene is located on chromosome 18q and someday the SMAD4 gene status may be useful for prognostic stratification and therapeutic decision. The cells respond to environmental signals by modulating the expressions of genes contained within the nucleus, when genes are activated are transcribed to generate messenger RNA (mRNA). The examination of multiple expressed genes and proteins provides more useful information for prognostication of individual tumors. Here we summarize and discuss findings presented at the 2014 ASCO Gastrointestinal Cancers Symposium. Anna Karpathakis et al. (Abstract #212) reported data about the role of DNA methylation in gastrointestinal neuroendocrine tumors. Christina Lynn Roland et al. (Abstract #250) looked the impact Of SMAD4 on oncologic outcomes. Bong Kynn Kang et al. (Abstract #251) investigated prognostic biomarker using microRNA array technology.

Image: Sotiria Hospital, Athens, Greece: The Museum of Salvation


Download data is not yet available.


Jensen RT. Carcinoid tumors and the carcinoid syndrome. In: De Vita VTJ, Lawrence, T., Rosenberg, S.A., ed. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott, Williams, and Wilkins; 2008.

Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;20:2633-42

Duerr EM, Chung DC. Molecular genetics of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab 2007; 21:1.

Anna Karpathakis A, Harpreet Dibra H, Tiffany Morris T, Dahmane Oukrife D, Christodoulos P Pipinikas CP, Kerra Pearce K, et al. Genome-wide DNA methylation profiling of gastrointestinal neuroendocrine tumors to identify hypermethylation of mTOR, Wnt, and Notch pathways in GI NET pathogenesis. J Clin Oncol 2014; 32(Suppl 3): Abstract 212.

Roland CL, Kang Y, Chatterjee D, Estrella J, Rashid A, Lee JE, et al. Loss of SMAD4 and effect on overall survival in resected gastrointestinal neuroendocrine tumors. J Clin Oncol 2014; 32(Suppl 3): Abstract 250. content/122676-143

Kang BK, Hwang IK, Lee YS, Kim J, Hwang JH. MicroRNA-27b as a prognostic marker in pancreatic neuroendocrine tumor. J Clin Oncol 2014; 32(Suppl 3): Abstract 251. http://meetinglibrary.

Sotiria Hospital, Athens, Greece: The Museum of Salvation
How to Cite
TheochariM., SyrigosK., & SaifM. (2014). Biomarkers in Pancreatic Neuroendocrine Tumors. JOP. Journal of the Pancreas, 15(2), 138-139.
Highlights from the “2014 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 16-18, 2014

Most read articles by the same author(s)

1 2 > >>